These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 28644861)

  • 41. High rate of Ki-67 increase in entero-pancreatic NET relapses after surgery with curative intent.
    Merola E; Perren A; Rinke A; Zerbi A; McNamara MG; Arsenic R; Fazio N; de Herder W; Valle JW; Gress TM; Wiedenmann B; Pascher A; Pavel ME
    J Neuroendocrinol; 2022 Oct; 34(10):e13193. PubMed ID: 36306194
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Characteristics, Treatment, Outcomes, and Survival in Neuroendocrine G1 and G2 Pancreatic Tumors: Experiences From a Single Tertiary Referral Center.
    Calissendorff J; Bjellerup-Calissendorff F; Bränström R; Juhlin CC; Falhammar H
    Front Endocrinol (Lausanne); 2021; 12():657698. PubMed ID: 33927695
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synaptophysin-Ki67 double stain: a novel technique that improves interobserver agreement in the grading of well-differentiated gastrointestinal neuroendocrine tumors.
    Matsukuma K; Olson KA; Gui D; Gandour-Edwards R; Li Y; Beckett L
    Mod Pathol; 2017 Apr; 30(4):620-629. PubMed ID: 28084345
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Can pancreatic neuroendocrine tumour biopsy accurately determine pathological characteristics?
    Rebours V; Cordova J; Couvelard A; Fabre M; Palazzo L; Vullierme MP; Hentic O; Sauvanet A; Aubert A; Bedossa P; Ruszniewski P
    Dig Liver Dis; 2015 Nov; 47(11):973-7. PubMed ID: 26169284
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic impact of tumour burden in stage IV neuroendocrine neoplasia: A comparison between pancreatic and gastrointestinal localizations.
    Panzuto F; Pusceddu S; Faggiano A; Rinzivillo M; Brighi N; Prinzi N; Riccardi F; Iannicelli E; Maggio I; Femia D; Tafuto S; Manuzzi L; Di Sarno A; Annibale B; de Braud F; Campana D;
    Pancreatology; 2019 Dec; 19(8):1067-1073. PubMed ID: 31587962
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pancreatic neuroendocrine tumour grading on endoscopic ultrasound-guided fine needle aspiration: high reproducibility and inter-observer agreement of the Ki-67 labelling index.
    Weynand B; Borbath I; Bernard V; Sempoux C; Gigot JF; Hubert C; Lannoy V; Deprez PH; Jouret-Mourin A
    Cytopathology; 2014 Dec; 25(6):389-95. PubMed ID: 24750272
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ki-67 and presence of liver metastases identify different progression-risk classes in pancreatic neuroendocrine neoplasms (pNEN) undergoing resection.
    Milione M; Maisonneuve P; Pellegrinelli A; Spaggiari P; Centonze G; Coppa J; Delconte G; Droz Dit Busset M; Lanhazo O; Pruneri G; Mazzaferro V
    Eur J Surg Oncol; 2019 May; 45(5):755-760. PubMed ID: 30366875
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Overexpression of ODF1 in Gastrointestinal Tract Neuroendocrine Neoplasms: a Novel Potential Immunohistochemical Biomarker for Well-differentiated Neuroendocrine Tumors.
    Li B; Li X; Mao R; Liu M; Fu L; Shi L; Zhao S; Fu M
    Endocr Pathol; 2021 Jun; 32(2):301-308. PubMed ID: 32869188
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinicopathological Profiling of Lung Carcinoids with a Ki67 Index > 20.
    Kasajima A; Konukiewitz B; Oka N; Suzuki H; Sakurada A; Okada Y; Kameya T; Ishikawa Y; Sasano H; Weichert W; Klöppel G
    Neuroendocrinology; 2019; 108(2):109-120. PubMed ID: 30485860
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas.
    Tang LH; Untch BR; Reidy DL; O'Reilly E; Dhall D; Jih L; Basturk O; Allen PJ; Klimstra DS
    Clin Cancer Res; 2016 Feb; 22(4):1011-7. PubMed ID: 26482044
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications.
    Fazio N; Milione M
    Cancer Treat Rev; 2016 Nov; 50():61-67. PubMed ID: 27636009
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Candidate protein biomarkers in pancreatic neuroendocrine neoplasms grade 3.
    Ali AS; Perren A; Lindskog C; Welin S; Sorbye H; Grönberg M; Janson ET
    Sci Rep; 2020 Jun; 10(1):10639. PubMed ID: 32606315
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Do morphologic characteristics play a role in nodal metastatic progression of well-differentiated pancreatic neuroendocrine tumors?
    Ugras N; Hasdemir S; Yerci Ö; Taşar P; Dündar HZ; Macunluoğlu AC
    Tumori; 2021 Feb; 107(1):80-85. PubMed ID: 32705937
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunohistochemical Study of Mitosis-regulatory Proteins in Gastroenteropancreatic Neuroendocrine Neoplasms.
    Briest F; Wang Y; Arsenic R; Elezkurtaj S; Berg E; Greshake S; Lock AC; Hörsch D; Arnold CN; Hummel M; Siegmund B; Grabowski P
    Anticancer Res; 2018 Jul; 38(7):3863-3870. PubMed ID: 29970506
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical validation of the gastrointestinal NET grading system: Ki67 index criteria of the WHO 2010 classification is appropriate to predict metastasis or recurrence.
    Yamaguchi T; Fujimori T; Tomita S; Ichikawa K; Mitomi H; Ohno K; Shida Y; Kato H
    Diagn Pathol; 2013 Apr; 8():65. PubMed ID: 23607525
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
    Cigrovski Berković M; Čačev T; Catela Ivković T; Marout J; Ulamec M; Zjačić-Rotkvić V; Kapitanović S
    Mol Cell Endocrinol; 2016 Apr; 425():61-8. PubMed ID: 26805636
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Grading of neuroendocrine tumors with Ki-67 requires high-quality assessment practices.
    Remes SM; Tuominen VJ; Helin H; Isola J; Arola J
    Am J Surg Pathol; 2012 Sep; 36(9):1359-63. PubMed ID: 22895268
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic differences in grading and metastatic lymph node pattern in patients with small bowel neuroendocrine tumors.
    Reinhard L; Mogl MT; Benz F; Dukaczewska A; Butz F; Dobrindt EM; Tacke F; Pratschke J; Goretzki PE; Jann H
    Langenbecks Arch Surg; 2023 Jun; 408(1):237. PubMed ID: 37332044
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Morphological and immunohistochemical features of neuroendocrine neoplasms in gastroenteropancreatic tract.
    Živojinov M; Panić Ž; Ilić A; Ilić Sabo J; Vasilijević M; Lakić T
    Arab J Gastroenterol; 2023 Feb; 24(1):24-28. PubMed ID: 35927198
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Analysis of 100 consecutive cases of resectable pancreatic neuroendocrine neoplasms: clinicopathological characteristics and long-term outcomes.
    Cheng Y; Zhan H; Wang L; Xu J; Zhang G; Zhang Z; Hu S
    Front Med; 2016 Dec; 10(4):444-450. PubMed ID: 27757796
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.